UNDERSTANDING THE NEED FOR ASSISTANCE WHEN COMPLETING MEASURES OF PATIENT-REPORTED OUTCOMES IN HUNTINGTON DISEASE

Similar documents
National & International Lectures

3/5/2014. New Research Initiatives to Improve QoL of Persons with SCI Across the Globe. What Are the SCI International Datasets?

ALLISON B. MUELLER 1007 W. Harrison Street (M/C 285), Chicago, Illinois Phone: (847)

PREDICT-HD. PREDICT-HD: Paving the Way Toward Clinical Trials. Dr. Jane Paulsen Principal Investigator PREDICT-HD

Allison B. Mueller 1007 W. Harrison Street (M/C 285), Chicago, Illinois Phone: (847)

NIH Toolbox. Technical Manual

Allison B. Mueller 1007 W. Harrison Street (M/C 285), Chicago, Illinois Phone: (847)

Richard C. Gershon, PhD.

Do you have myelofibrosis?

Understanding Huntington s disease (HD)

Two-item PROMIS global physical and mental health scales

Sources of Comparability Between Probability Sample Estimates and Nonprobability Web Sample Estimates

Vessel wall differences between middle cerebral artery and basilar artery. plaques on magnetic resonance imaging

IN A RECENT AMERICAN Congress of Rehabilitation

Instruments Available for Use in Assessment Center

PROMIS Overview: Development of New Tools for Measuring Health-related Quality of Life and Related Outcomes in Patients with Chronic Diseases

Quality of Life Instrument Development in Adults. American Cochlear Implant Alliance /8/18

LIHR La ricerca sulle malattie rare e le prospettive di cura per la malattia di Huntington. Neuroscience, the Future is Bright

Neuropsychological Correlates of Performance Based Functional Status in Elder Adult Protective Services Referrals for Capacity Assessments

PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES PROMIS SLEEP DISTURBANCE AND NEURO-QOL SLEEP DISTURBANCE

10/30/2013. Disclosures. Defining Flares in RA RA Flare Group

TBI Irritability, Aggression & Anger. A New Perspective on Anger and Aggression after TBI. Disclosures 9/13/2018. Grant support:

PPMI Cognitive-Behavioral Working Group. Daniel Weintraub, MD

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the FaSScinate Trial

Notes for laboratory session 2

Reliability and validity of the International Spinal Cord Injury Basic Pain Data Set items as self-report measures

PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES

Factor analysis of alcohol abuse and dependence symptom items in the 1988 National Health Interview survey

Using PROMIS to Assess Quality of Life for Children with Brain Tumors

AHRQ Effective Health Care Program Clinical and Comparative Effectiveness Research Methods: II

Cognitive Impairment and Magnetic Resonance Changes in Multiple Sclerosis. Background

NIH Toolbox. Technical Manual

Rapidly-administered short forms of the Wechsler Adult Intelligence Scale 3rd edition

Implementing PROMIS for Routine Screening in Ambulatory Cancer Care

Maurie Markman, MD, Series Editor

PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES PROMIS PEDIATRIC ANXIETY AND NEURO-QOL PEDIATRIC ANXIETY

MEASURING MEANING AND PEACE WITH THE FACIT-SP: DISTINCTION WITHOUT A DIFFERENCE?

Capturing the Effects of COMT Inhibition on Sequelae of Brain Injuries with NIHTB and TBI-QoL

Juvenile Huntington s Disease. Josh Dayananthan, MD Movement Disorders Fellow HDSA Center of Excellence at UC Davis Medical Center

Long-term Blood Pressure Variability throughout Young Adulthood and Cognitive Function in Midlife; CARDIA study

Chapter Two Incidence & prevalence

PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES

LIBRE Staff and Investigators

Choosing a Significance Test. Student Resource Sheet

2010 International Nanny Association Salary and Benefits Survey Information in this report is based on the year About Survey Respondents

ENROLL-DOC-2009-EN-1.0

The role of memory on patients with mild cognitive impairment. Sophia Vardaki, PhD National Technical University of Athens

Changes Over Time in Occurrence, Severity, and Distress of Common Symptoms During and After Radiation Therapy for Breast Cancer

Alison M. Mattek Department of Psychology, Stanford University 420 Serra Mall, Stanford, CA 94305

HDSA Annual Convention June 2013 Behavior Issues: Irritability and Depression Peg Nopoulos, M.D.

CSF Aβ1-42 predicts cognitive impairment in de novo PD patients

Gender-Based Differential Item Performance in English Usage Items

CRITICALLY APPRAISED PAPER

The Influence of Sleep on Cognition in Breast Cancer

Cover Page. The handle holds various files of this Leiden University dissertation

Table of Contents. Preface to the third edition xiii. Preface to the second edition xv. Preface to the fi rst edition xvii. List of abbreviations xix

Connectedness DEOCS 4.1 Construct Validity Summary

Patient Reported Outcomes in Sickle Cell Disease. Marsha J. Treadwell, PhD 5 October 2016

PROMIS PAIN INTERFERENCE AND BRIEF PAIN INVENTORY INTERFERENCE

Elderly Norms for the Hopkins Verbal Learning Test-Revised*

PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES PROMIS GLOBAL HEALTH-PHYSICAL AND VR-12- PHYSICAL

Clinical Guidelines. Annals of Internal Medicine. Annals of Internal Medicine

An Initial Validation of Virtual Human Administered Neuropsychological Assessments

RARE DISEASE WORKSHOP SERIES Improving the Clinical Development Process. Disclaimer:

ASSOCIATION OF PRE-TREATMENT DEPRESSION WITH QUALITY OF LIFE DURING AND AFTER RADIOTHERAPY FOR PROSTATE CANCER

The MHSIP: A Tale of Three Centers

Neural Prosthesis Seminar Series

Quality of Life Measurement in Neurodegenerative and Related Conditions

Neuropsychology and Parkinson s Disease. Erin Holker, Ph.D., ABPP Neuropsychology Laboratory

PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA

Progression of motor subtypes in Huntington s disease: a 6-year follow-up study

JOSHUA DANIEL WONDRA

Pediatric Otolaryngology Fellowship News & Events

PROMIS DEPRESSION AND NEURO-QOL DEPRESSION

Advanced Trauma Techniques

March 14, The Food and Drug Administration (FDA) is facing a serious crisis that has significant implications for the nation s health.

The Future of Measuring Patient-Reported Outcomes in Rheumatology

COGNITIVE FUNCTION. PROMIS Pediatric Item Bank v1.0 Cognitive Function PROMIS Pediatric Short Form v1.0 Cognitive Function 7a

Tuberculosis and Travel

Volunteering in Oklahoma City, OK

PROMIS ANXIETY AND KESSLER 6 MENTAL HEALTH SCALE PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES

Neuro-QOL and the NIH Toolbox: implications for epilepsy

Words: 1393 (excluding table and references) Exploring the structural relationship between interviewer and self-rated affective

PROMIS DEPRESSION AND CES-D

Protecting the gains: what changes are needed to prevent a reversal of the downward CVD mortality trend?

Parkinson s Foundation Nurse Course Faculty

2018 National Oncologists Workforce Study OCTOBER 2018

Incidence of Dravet Syndrome in a US Population

AAll s well that ends well; still the fine s the crown; Whate er the course, the end is the renown. WILLIAM SHAKESPEARE, All s Well That Ends Well

NEUROLOGIC DISORDERS and their treatments can affect

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative

PLOS Currents Huntington Disease

PROMIS ANXIETY AND MOOD AND ANXIETY SYMPTOM QUESTIONNAIRE PROSETTA STONE ANALYSIS REPORT A ROSETTA STONE FOR PATIENT REPORTED OUTCOMES

Neurobiology and Behavior, Ph.D. in progress University of California, Irvine; Irvine, CA


HIV/AIDS and other Sexually Transmitted Diseases (STDs) in the Southern Region of the United States: Epidemiological Overview

The Effects of Autocorrelated Noise and Biased HRF in fmri Analysis Error Rates

Aging Mastery Program Qualifications for Older Americans Act Title III-D Funding May 2018

Gender Differences in Adolescent Ego. Development and Ego Functioning Level

Transcription:

UNDERSTANDING THE NEED FOR ASSISTANCE WHEN COMPLETING MEASURES OF PATIENT-REPORTED OUTCOMES IN HUNTINGTON DISEASE Noelle E. Carlozzi, Ph.D. September 27, 2017

HUNTINGTON DISEASE (HD) https://youtu.be/jzaph2v-scq

A PRO MEASUREMENT SYSTEM THAT IS SPECIFIC TO HD Figure 1. Components of the HDQLIFE Measurement System HDQLIFE Generic Domains (Neuro - QoL & PROMIS) HD-Specific Domains Anxiety Anger Depression Emotional & Behavioral Dyscontrol Positive Affect and Well-Being Lower Extremity Function/Mobility Upper Extremity Function/ADLs Applied Cognition-Executive Functioning Applied Cognition-General Concerns Stigma Ability to Participate in Social Roles and Activities Satisfaction with Social Roles and Activities Chorea Difficulties with Speech & Swallowing End of Life Issues Concern with Death and Dying Meaning and Purpose Carlozzi, N.E., et al. (2016): HDQLIFE: Development and assessment of health-related quality of life in Huntington disease (HD). Quality of Life Research, 25(10), 2441-2455. New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient reported outcomes measurement system). Quality of Life Research, 25(10), 2403-2415. The development of a new computer adaptive test to evaluate chorea in Huntington Disease: HDQLIFE Chorea. Quality of Life Research, 25(10), 2429-2439. HDQLIFE: The development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties and Swallowing Difficulties. Quality of Life Research, 25(10), 2417-2427.

BACKGROUND PROs should be both reliable (i.e., repeatable) and valid (i.e., measure what was intended). Symptom progression in HD often includes cognitive decline, especially in the later stages. Can we determine when cognitive impairment may preclude PRO responding (i.e., large error variance and low reliability)?

HYPOTHESES Items on PROs should not exhibit item bias. PROs should demonstrate moderate relationships with observer reports of similar constructs. The variability and reliability for PROs should meet minimally acceptable standards.

SAMPLE CHARACTERISTICS N = 506 participants 38.8% prodromal 39.0% early-stage HD 22.5% late-stage HD Average age 49.0 (SD = 13.2) 58.5% female 95.3% Caucasian

MEASURES HDQLIFE PROs: Chorea (34 items) Speech Difficulties (27 items) Swallowing Difficulties (16 items) UHDRS clinician-rated assessments: Total Functional Capacity Total Motor Score Stroop (Color Naming, Word Reading, and Interference) Symbol Digit Modalities Test

ITEM BIAS Item bias was assessed using differential item functioning (DIF) both across HD stage and relative to cognitive performance. In general, items should not exhibit DIF. Some degree of DIF is considered acceptable. Some types of DIF are more problematic than others.

ITEM BIAS RESULTS Most items were free from DIF Chorea: no items consistently exhibited DIF; when DIF was present it was minimal Speech: 5 items exhibited DIF across cognitive tests and staging; no items consistently demonstrated non-uniform DIF Swallowing: 4 items consistently exhibited DIF across cognitive tests and staging; no items consistently exhibited non-uniform DIF Overall DIF was minimal

RELATIONSHIPS BETWEEN PROS AND CLINICIAN-RATED SYMPTOMS Pearson correlations between self-report and associated clinician ratings were examined. We expect moderate agreement between respondents (r s between 0.40 and 0.60).

RELATIONSHIPS BETWEEN SELF-REPORT AND CLINICIAN RATINGS PRO Measures Prodromal Early-HD Late-HD Combined Composite Scores Clinician-rated Total Motor Score Chorea Speech Swallowing Chorea Speech Swallowing Chorea Speech Swallowing Chorea Speech Swallowing.40.22.31.31.21.27.22.28.07.66.54.50

RELATIONSHIPS BETWEEN SELF-REPORT AND CLINICIAN RATINGS PRO Measures Prodromal Early-HD Late-HD Combined Composite Scores Clinician-rated Total Motor Score.. Chorea Speech Swallowing Chorea Speech Swallowing Chorea Speech Swallowing Chorea Speech Swallowing.40.22.31.31.21.27.22.28.07.66.54.50

PSYCHOMETRIC RELIABILITY OF PROS Three separate sets of regression models were examined to determine the psychometric reliability of the PROs 1. A simple linear regression model: split half reliabilities were compared 2. A heterogeneous variance model for HD stage: model was fit with different variances for each HD stage 3. A heterogeneous variance model for cognition: model was fit for variance in total cognition. Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Split-Half Correlations Item 3 Item 4 Item 5.91 Item 1 Item 2 Item 6

Reliability standards: 0.70 = unacceptable 0.70-0.79 = acceptable 0.80 0.89 = good 0.90 = excellent Table 4: Estimated PRO Reliabilities by HD Stage Measure Prodromal Early Late HDQLIFE Chorea 0.98 0.86 0.72 HDQLIFE Speech 0.98 0.85 0.69 HDQLIFE Swallowing 0.95 0.79 0.71

SIMPLE REGRESSION MODELS Table 3: Simple Regression Models PRO Measure beta R 2 t Chorea 0.97 0.94 83.22 Speech 0.92 0.92 70.93 Swallowing 1.24 0.84 49.18 Note. all p <.0001

MODEL FIT RESULTS FOR PRO MEASURES Model DF AIC BIC Chi-Square HDQLIFE Chorea Simple Regression 3 2291.75 2303.90 Heterogeneous - Cognition 4 2112.89 2129.09 180.86* Heterogeneous - HD Stage 5 2096.93 2117.18 198.81* HDQLIFE Speech Difficulties Simple Regression 3 2330.83 2343.12 Heterogeneous -Cognition 4 2239.79 2256.19 93.03* Heterogeneous - HD Stage 5 2206.81 2227.30 128.02* HDQLIFE Swallowing Difficulties Simple Regression 3 2136.32 2148.63 Heterogeneous -Cognition 4 1993.47 2009.88 144.85* Heterogeneous - HD Stage 5 2038.47 2058.94 101.85* Note. * p <.0001 The heterogeneous models provide a better fit than the simple regression model

15 Residual Plot: Chorea 10 variability Total Cognition Scores 5 variability Residual 0-5 variability -10 Prodromal HDHD -15 Late HDHD Early HDHD -20 0 50 100 150 200 250 300 350 400 450 Cognition Total Scores

CUTOFF SCORES FOR RELIABILITY PRO Reliability > 0.7 adequate Total Cognition Scores (SDMT + Stroop) Reliability > 0.8 good Chorea <77 < 136 Speech N/A <109 Swallowing <134 <179 Note. M = 144.56 (SD = 77.31) for Total Cognition Scores for the combined sample

SUMMARY & CONCLUSIONS As HD progresses and cognition declines, high error variance and low reliability can negatively affected the psychometric properties of PRO measures. Although minimal standards for reliability on PRO measures was met for all HD groups, clinical cutoffs on cognitive tests can be used to maximize PRO reliability. In cases where cognitive scores do not meet critical cutoffs, PRO measures should only be considered in conjunction with other assessments. Recommended clinical cutoffs differed for different measures. This suggests that cognitive complexity may vary across PRO measures.

QUESTIONS?

ACKNOWLEDGEMENTS Funding: National Institute of Neurological Disorders and Stroke: R01NS077946, R03NS065194, R01NS040068, & R01NS077946 National Center for Advancing Translational Sciences UL1TR000433 CHDI Foundation HD Center Grant from the NJ Department of Health and Senior Services HDQLIFE Site Investigators and Coordinators: Praveen Dayalu, Amy Austin (University of Michigan, Ann Arbor, MI); Courtney Shadrick, Amanda Miller (University of Iowa, Iowa City, IA); Kimberly Quaid, Melissa Wesson (Indiana University, Indianapolis, IN); Christopher Ross, Gregory Churchill, Mary Jane Ong (Johns Hopkins University, Baltimore, MD); Susan Perlman, Brian Clemente (University of California -Los Angeles, Los Angeles, CA); Michael McCormack, Humberto Marin, Allison Dicke (Rutgers University, Piscataway, NJ); Joel Perlmutter, Stacey Barton, Shineeka Smith (Washington University, St. Louis, MO); Martha Nance, Pat Ede (Struthers Parkinson s Center); Anwar Ahmed, Christine Reece, Lyla Mourany (Cleveland Clinic Foundation, Cleveland, OH); Michael Geschwind, Joseph Winer (University of California San Francisco, San Francisco, CA); David Cella, Richard Gershon, Elizabeth Hahn, Jin-Shei Lai (Northwestern University Chicago, IL)

CONTACT US Phone: 734 764-0644 E-mail: PMR-HDStudy@med.umich.edu https://sites.google.com/site/codaresearch/